Robert Driscoll
Stock Analyst at Wedbush
(3.26)
# 1,085
Out of 5,182 analysts
170
Total ratings
41.03%
Success rate
4.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Reiterates: Outperform | $147 | $144.83 | +1.50% | 10 | Apr 14, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $52 → $58 | $29.04 | +99.72% | 12 | Apr 14, 2026 | |
| REPL Replimune Group | Downgrades: Neutral | $19 → $2 | $2.57 | -22.18% | 9 | Apr 13, 2026 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $37 → $41 | $24.80 | +65.32% | 8 | Apr 2, 2026 | |
| EIKN Eikon Therapeutics | Reiterates: Underperform | $7 | $8.56 | -18.22% | 2 | Mar 31, 2026 | |
| APRE Aprea Therapeutics | Reiterates: Outperform | $7 | $0.84 | +736.42% | 5 | Mar 31, 2026 | |
| BDTX Black Diamond Therapeutics | Maintains: Outperform | $13 → $14 | $2.70 | +418.52% | 11 | Mar 17, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Outperform | $6 → $11 | $4.12 | +166.99% | 10 | Mar 17, 2026 | |
| FHTX Foghorn Therapeutics | Reiterates: Outperform | $10 | $5.17 | +93.42% | 8 | Mar 12, 2026 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $34 → $36 | $12.81 | +181.03% | 6 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $36 | $8.83 | +307.70% | 12 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $19 | $25.14 | -24.42% | 5 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $11 | $10.22 | +7.63% | 10 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $53 | $35.06 | +51.17% | 10 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $65.55 | +6.79% | 1 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $9.82 | +286.97% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $27 | $23.96 | +12.69% | 1 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $4.05 | -1.23% | 11 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $6 | $0.74 | +710.81% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $17 | $19.01 | -10.57% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $80 | $7.67 | +943.02% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $14.50 | +410.34% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.84 | +334.78% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.51 | +363.58% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $4.15 | -3.61% | 4 | May 19, 2020 |
Revolution Medicines
Apr 14, 2026
Reiterates: Outperform
Price Target: $147
Current: $144.83
Upside: +1.50%
IDEAYA Biosciences
Apr 14, 2026
Maintains: Outperform
Price Target: $52 → $58
Current: $29.04
Upside: +99.72%
Replimune Group
Apr 13, 2026
Downgrades: Neutral
Price Target: $19 → $2
Current: $2.57
Upside: -22.18%
Arcus Biosciences
Apr 2, 2026
Maintains: Outperform
Price Target: $37 → $41
Current: $24.80
Upside: +65.32%
Eikon Therapeutics
Mar 31, 2026
Reiterates: Underperform
Price Target: $7
Current: $8.56
Upside: -18.22%
Aprea Therapeutics
Mar 31, 2026
Reiterates: Outperform
Price Target: $7
Current: $0.84
Upside: +736.42%
Black Diamond Therapeutics
Mar 17, 2026
Maintains: Outperform
Price Target: $13 → $14
Current: $2.70
Upside: +418.52%
CytomX Therapeutics
Mar 17, 2026
Maintains: Outperform
Price Target: $6 → $11
Current: $4.12
Upside: +166.99%
Foghorn Therapeutics
Mar 12, 2026
Reiterates: Outperform
Price Target: $10
Current: $5.17
Upside: +93.42%
Cullinan Therapeutics
Mar 11, 2026
Maintains: Outperform
Price Target: $34 → $36
Current: $12.81
Upside: +181.03%
Mar 6, 2026
Maintains: Outperform
Price Target: $38 → $36
Current: $8.83
Upside: +307.70%
Mar 6, 2026
Maintains: Outperform
Price Target: $15 → $19
Current: $25.14
Upside: -24.42%
Feb 25, 2026
Maintains: Neutral
Price Target: $9 → $11
Current: $10.22
Upside: +7.63%
Feb 13, 2026
Maintains: Outperform
Price Target: $37 → $53
Current: $35.06
Upside: +51.17%
Dec 11, 2025
Initiates: Outperform
Price Target: $70
Current: $65.55
Upside: +6.79%
Oct 20, 2025
Maintains: Outperform
Price Target: $31 → $38
Current: $9.82
Upside: +286.97%
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $23.96
Upside: +12.69%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $4.05
Upside: -1.23%
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $0.74
Upside: +710.81%
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $19.01
Upside: -10.57%
Sep 20, 2024
Reiterates: Outperform
Price Target: $80
Current: $7.67
Upside: +943.02%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $14.50
Upside: +410.34%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $1.84
Upside: +334.78%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.51
Upside: +363.58%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $4.15
Upside: -3.61%